Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
MP79-07 VALIDATION AND IMPLEMENTATION OF A MOBILE APP DECISION SUPPORT SYSTEM FOR QUALITY ASSURANCE OF TUMOR BOARDS. ANALYZING THE CONCORDANCE RATES FOR PROSTATE CANCER AT A MULTIDISCIPLINARY TUMOR BOARD OF A TERTIARY REFERRAL CENTRE
0
Zitationen
8
Autoren
2020
Jahr
Abstract
approved for treatment of M0 CRPC. ARN-509 as neoadjuvant treatment in organ confined disease has not been studied before. The NEAR trial is a phase II single arm study of neoadjuvant apalutamide (ARN-509) and radical prostatectomy (RP) in the treatment of D'Amico intermediate and high-risk prostate cancer (Clinicaltrials.gov identifier: NCT03124433). This study aims to report on the oncological and pathological outcomes of neoadjuvant ARN-509 before RP.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.418 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.288 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.726 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.781 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.516 Zit.